DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: PLEGRIDY (pegylated interferon beta-1a)
       *****************************************************
       #Post#: 747--------------------------------------------------
       (AAN) Plegridy every 2 wks.  effective for RRMS 3 months after s
       tarting
       By: agate Date: April 28, 2015, 3:07 pm
       ---------------------------------------------------------
       This study, sponsored by Biogen, was presented at the annual AAN
       conference recently held in Washington, DC.
       [quote]S4.001] Peginterferon Beta-1a is Effective as Early as
       Twelve Weeks Following Treatment Initiation in Patients With
       Relapsing Multiple Sclerosis
       Scott Newsome,1Bernd Kieseier,2Shulian Shang,3Shifang
       Liu,3Serena Hung,3Bjoern Sperling3
       1Baltimore, MD, USA, 2Duesseldorf, Germany, 3Cambridge, MA, USA.
       OBJECTIVE:
       To investigate the early effects of subcutaneous peginterferon
       beta-1a (PEG-IFN) dosed every two weeks in patients with
       relapsing remitting multiple sclerosis (RRMS).
       BACKGROUND:
       In the Phase 3 ADVANCE study in patients with RRMS, PEG-IFN
       dosed at 125 μg every two weeks was more effective than
       placebo and had a safety profile similar to other beta
       interferons. This analysis evaluated the efficacy of PEG-IFN in
       patients following the initial three months of treatment in the
       same study.
       DESIGN/METHODS: ADVANCE was a two-year, multi-national,
       double-blind, placebo-controlled, Phase 3 study, in patients
       aged 18-65 years with RRMS. The current analysis evaluated the
       efficacy of PEG-IFN dosed every two weeks versus placebo within
       the first three months of treatment. Efficacy assessments,
       evaluated at 12 weeks, included the proportion of patients who
       relapsed, the annualized relapse rate (ARR), and the onset of
       24-week confirmed disability progression (CDP).
       RESULTS:
       The intent-to-treat population comprised 512 patients who
       received PEG-IFN and 500 patients who received placebo. At 12
       weeks of treatment:
       •
       was 6.0% versus 9.5% (p = 0.041) for PEG-IFN dosed every two
       weeks versus placebo, respectively;
       •
       patients receiving PEG-IFN every two weeks (0.240, 95% CI
       0.160-0.359) versus placebo (0.381, 95% CI 0.268-0.540);
       •
       CDP was 0.0% versus 1.0% (p = 0.026) for PEG-IFN every two weeks
       versus placebo, respectively.
       CONCLUSIONS:
       As early as three months after treatment initiation, PEG-IFN
       dosed every two weeks showed superior efficacy in reducing
       relapse, ARR, and CDP when compared with placebo.
       __________________
       Study sponsored by: Biogen Idec Inc. (Cambridge, MA, USA).
       Category - MS and CNS Inflammatory Disease: Clinical Science
       Session: S4: Platform Session: Clinical Trial Outcomes in
       Multiple Sclerosis (1:00 PM-2:45 PM)
       Date/Time: Tuesday, April 21, 2015 - 1:00 pm
       [/quote]
       The abstract can be seen here
  HTML http://www.abstracts2view.com/aan/view.php?nu=AAN15L1_S4.001.
       *****************************************************